A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women

Oncology

Volumn 64, Issue 2, 2003, Pages 116-123

  Yamazawa, Koji ^a   Matsui, Hideo ^a   Seki, Katsuyoshi ^a   Sekiya, Souei ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Endometrial cancer; Hyperprolactinemia; Premenopausal women; Risk factor

Indexed keywords

CHLORPROMAZINE; CLOCAPRAMINE; ESTRADIOL; ESTROGEN; FOLLITROPIN; LEVOMEPROMAZINE; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; PIMOZIDE; PROGESTERONE; PROLACTIN; RISPERIDONE; SULPIRIDE; SULTOPRIDE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; ENDOMETRIUM CARCINOMA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; OBESITY; PARITY; PREMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RISK ASSESSMENT; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CARCINOGENS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES COMPLICATIONS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HORMONES; HUMANS; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PARITY; PREMENOPAUSE; RISK ASSESSMENT; RISK FACTORS;

EID: 0037256791     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067769     Document Type: Article

References (28)

1. Ries L, Eisner M, Kosary C, Hankey BF, Miller BA, Clegg L, Edwards BK: SEER Cancer Statistics Review, 1973-1997. Bethesda, National Cancer Institute, 2000.
2. Osaka Foundation for Prevention of Cancer and Circulatory Disease: Cancer Incidence and Mortality in Osaka 1963-1989. Tokyo, Shinohara Publishers, 1993.
3. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
4. Sherman ME: Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod Pathol 2001;13:295-308.
5. Henderson BE, Ross RK, Pike MC, Casagrande JT: Endogenous hormones as major factor in human cancer. Cancer Res 1982;42:3232-3239.
6. Key TJA, Pike MC: The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-212.
7. Davies PH: Dug-related hyperprolactinaemia. Adverse Drug React Toxicol Rev 1997;16:83-94.
8. Greenman Y, Tordjman K, Stern N: Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels. Clin Endocrinol 1998;48:547-553.
9. Foss MC, Paula FJA, Paccola GMGF, Piccinato CE: Peripheral glucose metabolism in human hyperprolactinaemia. Clin Endocrinol 1995;43:721-726.
10. Demura R, Ono M, Demura H, Shizume K, Oouchi H: Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17β-estradiol in the human ovary. J Clin Endocrinol Metab 1982;54:1246-1250.
11. Henderson BE, Ross RK, Pike MC: Hormonal chemoprevention of cancer in women. Science 1993;259:633-638.
12. FIGO News: Corpus cancer staging. Int J Gynecol Obstet 1989;28:189-193.
13. Silverberg SG, Kurman RJ: Tumors of the uterine corpus and gestational trophoblastic disease; in Rosai J, Sobin LH (eds): Atlas of Tumor Pathology, ser 3. Washington, Armed Forces Institute of Pathology, 1992, pp 47-89.
14. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, Mendoza MT, Hernandez L: Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 1997;33:81-88.
15. Penninx BWJH, Guralnix JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ: Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998;90:1888-1893.
16. Winkelstein W Jr, Shillitoe EJ, Brand R, Johnson KK: Further comments on cancer of the uterine cervix, smoking, and herpes virus infection. Am J Epidemiol 1984;119:1-7.
17. LaBella FS, Brandes LJ: Enhancement of tumor growth by drugs with some common molecular actions. Mol Carcinog 1996;16:68-76.
18. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, Yajima A: Aromatase in human endometrial carcinoma and hyperplasia: Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995;146:491-500.
19. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR: Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997;94:6535-6540.
20. Jabbour HN, Critchley HOD, Boddy SC: Expression of functional prolactin receptors in nonpregnant human endometrium: Janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin. J Clin Endocrinol Metab 1998;83:2545-2553.
21. Petty RG: Prolactin and antipsychotic medications: Mechanism of action. Schizophr Res 1999;35:S67-73.
22. Tseng L, Mazella J, Chen G: Effect of relaxin on aromatase activity in human endometrial stromal cells. Endocrinology 1987;120:2220-2226.
23. Imai A, Furui T, Ohno T, Matsunami K, Takahashi K, Tamaya T: Prolactin binds to human endometrial fibroblasts and inhibits mitogenicity of an endometrial carcinoma extract. Proc Soc Exp Biol Med 1993;203:117-122.
24. Melmed S: Disorders of the anterior pituitary and hypothalamus; in Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds): Harrison's Principles of Internal Medicine, ed 15. New York, McGraw-Hill, 2001, pp 2038-2039.
25. Walsh JP, Bhagat CI, Pullan PT, Rampono JG: Drug-induced hyperprolactinemia. Med J Aust 1994;161:343.
26. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW: Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-1514.
27. Ferenczy A, Bertrand G, Gelfand MM: Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1979;133:859-867.
28. Dexeus S, Barri PN: Hyperprolactinemia: An inductor of neoplastic changes in endometrium? A report of two cases. Gynecol Endocrinol 1998;12:273-275.